Prehabilitation for people with cancer: Principles and guidance for prehabilitation within the management and support of people with cancer – Macmillan Cancer Support

Document published byThe Royal College of Anaesthetists, Macmillan Cancer Support, and the National Institute for Health Research (NIHR) Cancer and Nutrition Collaboration calling for changes to the delivery of cancer care across the UK, with a greater focus on prehabilitation

NHS Breast Screening Programme Equipment Report: Technical Evaluation of IMS Giotto Class digital mammography system in 2D mode – Public Health England

Technical evaluation of the IMS Giotto Class digital mammography system in 2D mode, used in the NHS breast screening programme.  Thisreport is one of a series of technical reports evaluating commercially available mammography systems on behalf of the NHS breast

Protocols for the surveillance of women at higher risk of developing breast cancer: Version 4 – Public Health England

The NHS breast surveillance protocols for women at higher risk of developing breast cancer.  Healthcare professionals working in the NHS breast screening programme should use these protocols.  They apply to women referred to the screening programme with a higher risk of developing

Screening Quality Assurance visit report: NHS Breast Screening Programme South Lancashire Breast Screening Service – Public Health England

Executive summary of quality assurance (QA) visit to South Lancashire Breast Screening Service, held on 13 March 2019.

Screening Quality Assurance visit report: NHS Bowel Cancer Screening Programme Lancashire – Public Health England

Executive summary of quality assurance (QA) visit to Lancashire bowel cancer screening service, held on 28 and 29 November 2018.  

Screening Quality Assurance visit report: NHS Bowel Cancer Screening Programme Bristol and Weston – Public Health England

This document collects findings from the quality assurance visit to Bristol and Weston, held on 15 and 16 January 2019.  The visit evaluated the bowel cancer screening programme, and was conducted by the PHE screening quality assurance service (SQAS).

Understanding the societal impact of treatment of early breast cancer: What are the non-clinical outcomes associated with disease progression? – RAND Europe

RAND Europe report that finds: Existing effective treatment for early breast cancer may lead policymakers and payers to underestimate the need for investment in further improvements and innovation in treatment and delivery of care in early breast cancer. The cost

Why do patients with a curative treatment plan for oesophago-gastric cancer not go on to receive surgery? – National Oesophago-Gastric Cancer Audit

The main curative treatment for patients with localised OG cancer is to remove the tumour with surgery (usually along with receiving chemotherapy or chemo-radiotherapy). As many OG patients are diagnosed with the condition at an advanced stage, only 30% of

Test Site Top Tips: Learning from the Faster Diagnosis Standard Test Sites – NHS England

This handbook contains tips from the five Faster Diagnosis Standard (FDS) test sites, who worked collaboratively with NHS England to: Robustly test and develop the rules for the faster diagnosis standard Explore impact on patients and the clinical services of

Clinical Commissioning Policy: 18Ffluorodeoxyglucose (FDG) positron emission tomography-computedtomography (PET CT) as part of radical radiotherapy treatment planning for oesophageal cancer (all ages) – NHS England

NHS England will not routinely commission 18F-FDG-PET CT as part of radical radiotherapy treatment planning for oesophageal cancer in accordance with the criteria outlined in this document. In creating this policy NHS England has reviewed this clinical condition and the

Clinical Commissioning Policy Statement: Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages) [170117P] – NHS England

This policy statement is to confirm that pazopanib is not recommended as a treatment option for inoperable and metastatic malignant granular cell tumours (all ages).  

Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages): Clinical Panel Report – NHS England

Clinical Panel report on Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages). This policy statement is to confirm that pazopanib is not recommended as a treatment option for inoperable and metastatic malignant granular cell tumours (all ages).

Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages): Clinical Priorities Advisory Group Report – NHS England

Clinical Priorities Advisory Group report on Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages). This policy statement is to confirm that pazopanib is not recommended as a treatment option for inoperable and metastatic malignant granular cell tumours

Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages): Engagement Report – NHS England

Engagement report on Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages). This policy statement is to confirm that pazopanib is not recommended as a treatment option for inoperable and metastatic malignant granular cell tumours (all ages).